



Oxford Brain Diagnostics to Provide Innovative MRI-based Metrics for NeuroTherapia's Alzheimer's Phase 2 Clinical Trial

Cutting-edge analysis of grey matter quality will offer detailed insights into brain health, aiding the assessment of NTRX-07's therapeutic potential in slowing Alzheimer's disease progression.

Oxford, United Kingdom, 7th October 2024.

Aiming to push the boundaries of Alzheimer's research, Oxford Brain Diagnostics has been appointed to evaluate drug efficacy in a phase 2 clinical trial for NeuroTherapia. NTRX-07, an orally available small molecule, is an innovative drug treatment designed to combat neuroinflammation, a key driver of Alzheimer's disease progression. Using Cortical Disarray Measurement (CDM[®]) from Oxford Brain Diagnostics will deliver advanced insights into brain structure and grey matter quality throughout the trial.

Oxford Brain Diagnostics' proprietary CDM technology analyses MRI scans to assess brain microstructure at various stages of the clinical trial. By examining grey matter quality across the entire brain and in specific regions, researchers can monitor disease progression and detect subtle structural changes. "We are thrilled to contribute our advanced imaging technologies to NeuroTherapia's pioneering Alzheimer's research," said Dr Steven Chance (CEO, Co-Founder) at Oxford Brain Diagnostics. "Our MRI-based technique provides an understanding of the microstructural changes associated with neuroinflammation, enhancing our knowledge of NTRX-07's therapeutic efficacy and paving the way for innovative treatments for neurodegenerative diseases."

NeuroTherapia's NTRX-07 compound is designed to modulate microglia - the immune cells of the central nervous system - to protect brain cells and lower harmful amyloid beta levels. "Partnering with Oxford Brain Diagnostics allows us to deepen our understanding of NTRX-07's impact," said Tony Gordano, PhD, (President and CEO) at NeuroTherapia. "Their CDM technology will give us crucial insights into grey matter changes, furthering our evaluation of this promising therapeutic."

About Oxford Brain Diagnostics Ltd - Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company's Cortical Disarray Measurement (CDM[®]) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer's and other neurodegenerative diseases.

For more information, visit <https://www.oxfordbraindiagnostics.com>

Contact: Omar Ehsan, Chief Commercial Officer; omar.ehsan@oxfordbraindiagnostics.com

About NeuroTherapia Inc. - NeuroTherapia is a clinical-stage, privately held biotechnology company developing oral, small-molecule drugs to address neuro-inflammatory conditions of the central nervous system (CNS), including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other CNS conditions. There is an emerging consensus that neuroinflammation plays a significant role in CNS disease. NeuroTherapia is developing therapeutics that inhibit microglia cells, which are known to express proteins that drive inflammation in the CNS, without affecting the clearance of toxic beta amyloid. We believe this approach will result in improved neuronal function and survival. At NeuroTherapia, our mission is to change the course of the most debilitating and deadly CNS diseases that patients and their families face today.

For more information, visit <http://www.neurotherapia.com/>

Contact: Tony Giordano, President and CEO, tony@neurotherapia.com

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.